BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 37560967)

  • 21. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
    Akova M; Unal S
    Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy of a novel inhibitor of vascular adhesion protein-1 in reducing albuminuria in patients with diabetic kidney disease (ALBUM): a randomised, placebo-controlled, phase 2 trial.
    de Zeeuw D; Renfurm RW; Bakris G; Rossing P; Perkovic V; Hou FF; Nangaku M; Sharma K; Heerspink HJL; Garcia-Hernandez A; Larsson TE
    Lancet Diabetes Endocrinol; 2018 Dec; 6(12):925-933. PubMed ID: 30413396
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Umbilical cord-derived mesenchymal stromal cells preserve endogenous insulin production in type 1 diabetes: a Phase I/II randomised double-blind placebo-controlled trial.
    Carlsson PO; Espes D; Sisay S; Davies LC; Smith CIE; Svahn MG
    Diabetologia; 2023 Aug; 66(8):1431-1441. PubMed ID: 37221247
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The kidney and cardiovascular outcome trials.
    Bloomgarden Z
    J Diabetes; 2018 Feb; 10(2):88-89. PubMed ID: 29031006
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Association of Finerenone Use With Reduction in Treatment-Emergent Pneumonia and COVID-19 Adverse Events Among Patients With Type 2 Diabetes and Chronic Kidney Disease: A FIDELITY Pooled Secondary Analysis.
    Pitt B; Agarwal R; Anker SD; Ruilope LM; Rossing P; Ahlers C; Brinker M; Joseph A; Lambelet M; Lawatscheck R; Filippatos GS;
    JAMA Netw Open; 2022 Oct; 5(10):e2236123. PubMed ID: 36287567
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial.
    Heerspink HJL; Parving HH; Andress DL; Bakris G; Correa-Rotter R; Hou FF; Kitzman DW; Kohan D; Makino H; McMurray JJV; Melnick JZ; Miller MG; Pergola PE; Perkovic V; Tobe S; Yi T; Wigderson M; de Zeeuw D;
    Lancet; 2019 May; 393(10184):1937-1947. PubMed ID: 30995972
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy and safety of intramuscular administration of allogeneic adipose tissue derived and expanded mesenchymal stromal cells in diabetic patients with critical limb ischemia with no possibility of revascularization: study protocol for a randomized controlled double-blind phase II clinical trial (The NOMA Trial).
    Soria-Juan B; Garcia-Arranz M; Llanos Jiménez L; Aparicio C; Gonzalez A; Mahillo Fernandez I; Riera Del Moral L; Grochowicz L; Andreu EJ; Marin P; Castellanos G; Moraleda JM; García-Hernández AM; Lozano FS; Sanchez-Guijo F; Villarón EM; Parra ML; Yañez RM; de la Cuesta Diaz A; Tejedo JR; Bedoya FJ; Martin F; Miralles M; Del Rio Sola L; Fernández-Santos ME; Ligero JM; Morant F; Hernández-Blasco L; Andreu E; Hmadcha A; Garcia-Olmo D; Soria B
    Trials; 2021 Sep; 22(1):595. PubMed ID: 34488845
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Nonalbuminuric Diabetic Kidney Disease and Risk of All-Cause Mortality and Cardiovascular and Kidney Outcomes in Type 2 Diabetes: Findings From the Hong Kong Diabetes Biobank.
    Jin Q; Luk AO; Lau ESH; Tam CHT; Ozaki R; Lim CKP; Wu H; Jiang G; Chow EYK; Ng JK; Kong APS; Fan B; Lee KF; Siu SC; Hui G; Tsang CC; Lau KP; Leung JY; Tsang MW; Kam G; Lau IT; Li JK; Yeung VT; Lau E; Lo S; Fung S; Cheng YL; Chow CC; Huang Y; Lan HY; Szeto CC; So WY; Chan JCN; Ma RCW;
    Am J Kidney Dis; 2022 Aug; 80(2):196-206.e1. PubMed ID: 34999159
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A Prospective Study to Evaluate the Possible Role of Cholecalciferol Supplementation on Autoimmunity in Hashimoto's Thyroiditis.
    Bhakat B; Pal J; Das S; Charaborty SK; SircarMedical NR; Kolkata ; RGKar ; NorthBengal ; Siliguri
    J Assoc Physicians India; 2023 Jan; 71(1):1. PubMed ID: 37116030
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Protein restriction for diabetic kidney disease.
    Jiang S; Fang J; Li W
    Cochrane Database Syst Rev; 2023 Jan; 1(1):CD014906. PubMed ID: 36594428
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Novel Renal Autologous Cell Therapy for Type 2 Diabetes Mellitus Chronic Diabetic Kidney Disease: Clinical Trial Design.
    Stavas J; Gerber D; Coca SG; Silva AL; Johns A; Jain D; Bertram T; Díaz-González de Ferris M; Bakris G
    Am J Nephrol; 2022; 53(1):50-58. PubMed ID: 35034024
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial: baseline characteristics.
    Wheeler DC; Stefansson BV; Batiushin M; Bilchenko O; Cherney DZI; Chertow GM; Douthat W; Dwyer JP; Escudero E; Pecoits-Filho R; Furuland H; Górriz JL; Greene T; Haller H; Hou FF; Kang SW; Isidto R; Khullar D; Mark PB; McMurray JJV; Kashihara N; Nowicki M; Persson F; Correa-Rotter R; Rossing P; Toto RD; Umanath K; Van Bui P; Wittmann I; Lindberg M; Sjöström CD; Langkilde AM; Heerspink HJL
    Nephrol Dial Transplant; 2020 Oct; 35(10):1700-1711. PubMed ID: 32862232
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Randomized, double-blind, placebo-controlled phase 3 study of bardoxolone methyl in patients with diabetic kidney disease: design and baseline characteristics of the AYAME study.
    Nangaku M; Takama H; Ichikawa T; Mukai K; Kojima M; Suzuki Y; Watada H; Wada T; Ueki K; Narita I; Kashihara N; Kadowaki T; Hase H; Akizawa T
    Nephrol Dial Transplant; 2023 May; 38(5):1204-1216. PubMed ID: 36002026
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of Keluoxin capsule combined with losartan potassium on diabetic kidney disease: study protocol for a randomized double-blind placebo-controlled multicenter clinical trial.
    Wu R; Wei F; Qu L; Bai L; Li J; Li F; Yan W; Wang Q; Wei J
    Trials; 2020 Nov; 21(1):951. PubMed ID: 33228726
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Metabolomic Markers of Kidney Function Decline in Patients With Diabetes: Evidence From the Chronic Renal Insufficiency Cohort (CRIC) Study.
    Kwan B; Fuhrer T; Zhang J; Darshi M; Van Espen B; Montemayor D; de Boer IH; Dobre M; Hsu CY; Kelly TN; Raj DS; Rao PS; Saraf SL; Scialla J; Waikar SS; Sharma K; Natarajan L;
    Am J Kidney Dis; 2020 Oct; 76(4):511-520. PubMed ID: 32387023
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Design and Baseline Characteristics of the Finerenone in Reducing Cardiovascular Mortality and Morbidity in Diabetic Kidney Disease Trial.
    Ruilope LM; Agarwal R; Anker SD; Bakris GL; Filippatos G; Nowack C; Kolkhof P; Joseph A; Mentenich N; Pitt B;
    Am J Nephrol; 2019; 50(5):345-356. PubMed ID: 31665733
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Race-free estimated glomerular filtration rate equation in kidney transplant recipients: development and validation study.
    Raynaud M; Al-Awadhi S; Juric I; Divard G; Lombardi Y; Basic-Jukic N; Aubert O; Dubourg L; Masson I; Mariat C; Prié D; Pernin V; Le Quintrec M; Larson TS; Stegall MD; Bikbov B; Ruggenenti P; Mesnard L; Ibrahim HN; Nielsen MB; Matas AJ; Nankivell BJ; Benjamens S; Pol RA; Bakker SJL; Jouven X; Legendre C; Kamar N; Smith BH; Wadei HM; Durrbach A; Vincenti F; Remuzzi G; Lefaucheur C; Bentall AJ; Loupy A
    BMJ; 2023 May; 381():e073654. PubMed ID: 37257905
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Diagnostic value of the Modification of Diet in Renal Disease and Chronic Kidney Disease Epidemiology Collaboration equations in diabetic patients: a systematic review and meta-analysis.
    Lingli X; Qing Z; Wenfang X
    J Int Med Res; 2020 Jun; 48(6):300060520925950. PubMed ID: 32589856
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Renal Autologous Cell Therapy in Type 2 Diabetes with Late Stage 4 Diabetes-Related Chronic Kidney Disease: Trial Design and Early Analysis.
    Stavas J; Thajudeen B; Coca S; Silva A; Butler E; Detwiler R; Burgner A
    Blood Purif; 2023; 52(2):114-121. PubMed ID: 36599315
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial.
    Wheeler DC; Stefánsson BV; Jongs N; Chertow GM; Greene T; Hou FF; McMurray JJV; Correa-Rotter R; Rossing P; Toto RD; Sjöström CD; Langkilde AM; Heerspink HJL;
    Lancet Diabetes Endocrinol; 2021 Jan; 9(1):22-31. PubMed ID: 33338413
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.